Equillium(US:EQ)2025-11-13 21:10Financial Performance - Revenue for Q3 2025 was $0, a decrease from $12.2 million in Q3 2024[8] - R&D expenses for Q3 2025 were $1.3 million, down 86.4% from $9.6 million in Q3 2024[9] - G&A expenses remained unchanged at $3.3 million for Q3 2025 compared to Q3 2024[10] - Net loss for Q3 2025 was $4.2 million, compared to a net loss of $7,000 in Q3 2024[10] - Cash, cash equivalents, and short-term investments totaled $33.1 million as of September 30, 2025, up from $22.6 million at the end of 2024[11] - Total stockholders' equity increased to $30.9 million as of September 30, 2025, from $19.1 million at the end of 2024[18] Financing and Funding - The company closed financing of up to $50 million, with an initial tranche of $30 million expected to fund operations through 2027[4] Clinical Development - EQ504 Phase 1 clinical study is expected to initiate in mid-2026[7] - The company aims to achieve proof-of-concept for EQ504 with the addition of ulcerative colitis patient cohorts following the SAD/MAD portion of the study[3] - The company hosted a KOL event discussing the potential of EQ504 in treating ulcerative colitis[5]